Nanovaccines against Viral Infection

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 583

Special Issue Editors


E-Mail Website
Guest Editor
College of Animal Sciences, Jilin University, Changchun 130062, China
Interests: porcine circovirus (PCV); pseudorabies virus (PRV); porcine epidemic diarrhea virus (PEDV); porcine deltacoronavirus (PDCoV); SeACoV (swine enteric alphacoronavirus)/SADS-CoV (swine acute diarrhea syndrome coronavirus); other emerging or re-emerging viruses; vaccine; antibody
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Nanjing, China
Interests: molecular epidemiology and investigating the pathogenic mechanisms of animal viruses; novel vaccines; nanobodies; Newcastle disease; avian influenza; canine parvovirus; feline panleukopenia; Brucella

E-Mail Website
Guest Editor
College of Animal Science, Yangtze University, Jingzhou, China
Interests: molecular virology; virus prevention and control; vaccine

Special Issue Information

Dear Colleagues,

Viral diseases, especially life-threatening pathogens such as SARS-CoV-2, smallpox, influenza and ASFV, have substantial implications on public and animal health, and subsequently global economies. Vaccination is a crucial approach to combat existing and emerging viruses. However, optimizing the potency, improving the quality and enhancing the durability of immune responses remain challenges. Nanoparticles could be an effective method for developing novel vaccinations. Nanovaccines trigger a robust immune response, allowing for diseases to be controlled or killed and spread to a minimum. They are designed such that the antigen can be on the exterior or inside the nanoparticles, allowing for efficient distribution. As a result, an encapsulated antigen is more difficult to break down, and the release is more tightly regulated at the target region. Controlled antigen release prevents an exaggerated reaction and eliminates the need for booster doses. In this Special Issue, we aim to present nanoantibodies and nanovaccines against viral infection. An emphasis will be placed on the reports focused on designing and evaluating nanoparticles, nano-based adjuvants, nanoantibodies, etc. Original research articles and reviews are welcome.

Prof. Dr. Linzhu Ren
Dr. Jing Qian
Dr. Fuxian Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticle
  • nanoantibody
  • nanovaccine
  • peptide-based nanovaccine
  • adjuvant and nanoadjuvant
  • antigen
  • nanotechnology in virus research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2348 KiB  
Article
Chimeric Virus-like Particles of Physalis Mottle Virus as Carriers of M2e Peptides of Influenza a Virus
by Elena A. Blokhina, Eugenia S. Mardanova, Anna A. Zykova, Marina A. Shuklina, Liudmila A. Stepanova, Liudmila M. Tsybalova and Nikolai V. Ravin
Viruses 2024, 16(11), 1802; https://doi.org/10.3390/v16111802 - 20 Nov 2024
Viewed by 327
Abstract
Plant viruses and virus-like particles (VLPs) are safe for mammals and can be used as a carrier/platform for the presentation of foreign antigens in vaccine development. The aim of this study was to use the coat protein (CP) of Physalis mottle virus (PhMV) [...] Read more.
Plant viruses and virus-like particles (VLPs) are safe for mammals and can be used as a carrier/platform for the presentation of foreign antigens in vaccine development. The aim of this study was to use the coat protein (CP) of Physalis mottle virus (PhMV) as a carrier to display the extracellular domain of the transmembrane protein M2 of influenza A virus (M2e). M2e is a highly conserved antigen, but to induce an effective immune response it must be linked to an adjuvant or carrier VLP. Four tandem copies of M2e were either fused to the N-terminus of the full-length PhMV CP or replaced the 43 N-terminal amino acids of the PhMV CP. Only the first fusion protein was successfully expressed in Escherichia coli, where it self-assembled into spherical VLPs of about 30 nm in size. The particles were efficiently recognized by anti-M2e antibodies, indicating that the M2e peptides were exposed on the surface. Subcutaneous immunization of mice with VLPs carrying four copies of M2e induced high levels of M2e-specific IgG antibodies in serum and protected animals from a lethal influenza A virus challenge. Therefore, PhMV particles carrying M2e peptides may become useful research tools for the development of recombinant influenza vaccines. Full article
(This article belongs to the Special Issue Nanovaccines against Viral Infection)
Show Figures

Figure 1

Back to TopTop